Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628028 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3337641 in Rheumatoid Arthritis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT02628028: Clinical Trial Phase 2 study, sponsored by Eli Lilly and Company.
NCT02628028 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 286 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02628028, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).
Primary Outcome
TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. Skin Rash was the only event that was considered an AESI. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant
Interventions
- DRUG Placebo
- DRUG LY3337641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2016-08-22 |
| Est. Completion | 2018-08-15 |
| Phase | Phase 2 |
Why NCT02628028 stopped before completion
NCT02628028 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02628028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02628028 about?
NCT02628028 is a clinical study titled "A Study of LY3337641 in Rheumatoid Arthritis". The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).
What is the current status of trial NCT02628028?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2016-08-22. Estimated completion is 2018-08-15.
What interventions are being tested in trial NCT02628028?
The interventions under investigation include: Placebo (DRUG), LY3337641 (DRUG).
Who is sponsoring clinical trial NCT02628028?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02628028's enrollment target sits among peer trials
286 191st of 2000 higher than 1,809 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI